Brand Intelligence Graph
Company Overview
About Cytotheryx
Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.
Business Model & Competitive Advantage
The core innovation is using proprietary genetically engineered pigs whose livers can host and expand functional human hepatocytes — a process called xenogeneic amplification. Human hepatocytes produced this way maintain their functional properties (drug metabolism, protein synthesis, bile production) and can be cryopreserved and distributed as an off-the-shelf therapeutic product. This addresses a critical bottleneck in liver disease treatment: human hepatocytes are in chronic short supply because they cannot be meaningfully expanded in vitro.
Competitive Landscape 2025–2026
Cytotheryx's pipeline has two near-term applications: bioartificial liver support for patients in acute liver failure (where a hepatocyte-seeded extracorporeal device buys time for liver recovery or transplant), and cell transplantation for metabolic liver diseases where replacing a subset of dysfunctional hepatocytes could be curative. The Mayo Clinic pedigree provides both clinical relationships and rigorous translational research infrastructure.
Key Differentiators
Emerging Innovator
Cytotheryx is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Cytotheryx with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cytotheryx? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cytotheryx Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cytotheryx vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →